Introduction: Pharmacy Solutions, a licensed specialty pharmacy, owned and operated by AbbVie, fills adalimumab (ADA) (HUMIRA®) prescriptions and offers a Nurse Care Management program, administered by registered nurses for 24 h/day, 7 d/week to answer patients (pts)' questions about their disease state, medication, and treatment through the course of therapy. We evaluated pts' hesitancy toward treatment with ADA while enrolled in a Nurse Care Management program. Methods: We performed a retrospective analysis on pts ≥18 years old with IBD, rheumatoid arthritis (RA), plaque psoriasis (Ps), and psoriatic arthritis (PsA), who enrolled in the nurse care management program and filled their ADA through Pharmacy Solutions from 2010-2015. Pts self-reported their hesitancy toward treatment before and after (final assessment) treatment, ranking it on a Likert scale from 0 to 5 (0=least hesitant, 5=most hesitant); reasons for hesitancy were not required, but were captured for some pts. Pts with ≥2 assessments were included in the analysis. Results: From 2010-2015, 1030 pts participated in the care management program. Majority of pts were female (657, 63.8%); 376 (36.5%) pts had RA, 268 (26.0%) IBD, 240 (23.3%) Ps, and 146 (14.2%) PsA. Hesitancy scores before and after therapy in 626 pts who completed ≥2 assessments of hesitancy are shown in the table. The number of pts with hesitancy=0 before and after treatment increased from 69 to 83 (42.6% to 51.6%) for IBD, 90 to 116 (42.5% to 55%) for RA, 98 to 117 (59.4% to 71.8%) for Ps, and 51 to 58 (58.6% to 67.4%) for PsA. Overall, the median difference between before and after scores was 1.5 (95% CI 1-∞; P< 0.001; Wilcoxon signed rank test). A total of 202/626 (32.2%) pts changed their hesitancy toward treatment after the final assessment: 179/202 (88.6%) became less hesitant, 23/202 (11.4%) became more hesitant. The proportion of pts, who decreased hesitancy from before scores of 3-5 to after scores of 0-2, was 25/89 (28.1%) for IBD, 32/89 (36.0%) for RA, 20/89 (22.5%) for Ps, 12/89 (13.5%) for PsA. Reasons for hesitancy, reported by 59 pts, included safety concerns (n=31), taking an injectable medication (n=9), needle phobia (n=6), the lack of efficacy from other biologics (n=1), and other reasons (n=12).Table 1: Hesitancy Score Before and After Treatment for Pts Enrolled in The Nurse Care Management ProgramConclusion: Hesitancy towards ADA therapy decreased in a large proportion of pts with IBD, RA, Ps, and PsA after initiating therapy and while enrolled in the Nurse Care Management program.